01311nas a2200241   4500000000100000008004100001260001700042653003200059653001100091653002100102653002100123653002300144653001200167100001400179700001500193700001600208245004300224300001100267490000700278050003200285520073800317022001401055       1994                            d  c1994 Jul-Sep10aAntibodies, Anticardiolipin10aHumans10aImmunoglobulin G10aImmunoglobulin M10aLeprostatic Agents10aleprosy1 aThawani G1 aBhatia V N1 aMukherjee A00aAnticardiolipin antibodies in leprosy.  a307-140 v66  aInfolep Library - available3 a<p>Eighty-four leprosy patients were studied clinically and for IgG and IgM anticardiolipin (aCL) antibodies. Following WHO criteria, 41 patients could be classified as multibacillary (MB) and 43 as paucibacillary (PB). Baseline levels of IgG and IgM antibodies were 27 +/- 4.8 GPL and 20 +/- 3.4 MPL per ml respectively. Comparing with these, 60.9% of MB and 39.5% of PB cases showed rise in IgG and IgM anticardiolipin antibodies; 19.5% of MB and 4.6% of PB sera showed rise in only IgG antibodies, while 4.8% of MB and 13.9% of PB cases showed rise only in IgM antibodies. Rise in aCL antibodies had no correlation with cardiovascular involvement, bacteriological index, reactive state and duration or regularity of treatment.</p>  a0254-9395